Type 2 diabetes mellitus as a conformational disease.

Conformational diseases are conditions that arise from the dysfunctional aggregation of proteins in non-native conformations. Type 2 diabetes mellitus can be defined as a conformational disease because a constituent beta cell protein, islet amyloid polypeptide, undergoes a change in tertiary structure followed by self-association and tissue deposition. Type 2 diabetes mellitus is associated with multiple metabolic derangements that result in the excessive production of reactive oxygen species and oxidative stress. These reactive oxygen species set in motion a host of redox reactions which can result in unstable nitrogen and thiol species that contribute to additional redox stress. The ability of a cell to deal with reactive oxygen species and oxidative stress requires functional chaperones, antioxidant production, protein degradation and a cascade of intracellular events collectively known as the unfolded protein response. It is known that beta cells are particularly susceptible to perturbations in this quality control system and that reactive oxygen species play an important role in the development and/or progression of diabetes mellitus. Oxidative stress and increased insulin production contribute to endoplasmic reticulum stress, protein misfolding, and induction of the unfolded protein response. As the cell's quality control system becomes overwhelmed, conformational changes occur to islet amyloid polypeptide intermediates, generating stable oligomers with an anti-parallel crossed beta-pleated sheet structure that eventually accumulate as space-occupying lesions within the islets. By approaching type 2 diabetes mellitus as a conformational disease in which there is a structural transition from physiological protein to pathological protein, it is possible that the relentless nature of disease progression can be understood in relation to other conformational diseases.

[1]  H. Sies Oxidative stress: from basic research to clinical application. , 1991, The American journal of medicine.

[2]  C. Dobson,et al.  Protein aggregation and aggregate toxicity: new insights into protein folding, misfolding diseases and biological evolution , 2003, Journal of Molecular Medicine.

[3]  P. Csermely,et al.  Molecular chaperones, stress proteins and redox homeostasis , 2003, BioFactors.

[4]  D. Lomas,et al.  The mechanism of Z alpha 1-antitrypsin accumulation in the liver. , 1992, Nature.

[5]  D. Piston,et al.  Oxidative Stress Is a Mediator of Glucose Toxicity in Insulin-secreting Pancreatic Islet Cell Lines* , 2004, Journal of Biological Chemistry.

[6]  A. Clark,et al.  beta-cell neogenesis in type 2 diabetes. , 2001, Diabetes.

[7]  R. Robertson Chronic Oxidative Stress as a Central Mechanism for Glucose Toxicity in Pancreatic Islet Beta Cells in Diabetes* , 2004, Journal of Biological Chemistry.

[8]  R. Cohen,et al.  Oxidation of the zinc-thiolate complex and uncoupling of endothelial nitric oxide synthase by peroxynitrite. , 2002, The Journal of clinical investigation.

[9]  J. Bernhagen,et al.  Amyloidogenicity of recombinant human pro-islet amyloid polypeptide (ProIAPP). , 2000, Chemistry & biology.

[10]  A. Ceriello,et al.  Detection of nitrotyrosine in the diabetic plasma: evidence of oxidative stress , 2001, Diabetologia.

[11]  A. Shapiro,et al.  Successful islet transplantation: continued insulin reserve provides long-term glycemic control. , 2002, Diabetes.

[12]  K. Xiang,et al.  [The impact of the missense mutation-ser20gly in islet amyloid polypeptide gene on NIDDM in Chinese]. , 1998, Zhonghua yi xue za zhi.

[13]  D. Pipeleers,et al.  Rapid deposition of amyloid in human islets transplanted into nude mice , 1995, Diabetologia.

[14]  Masataka Mori,et al.  Targeted disruption of the Chop gene delays endoplasmic reticulum stress-mediated diabetes. , 2002, The Journal of clinical investigation.

[15]  A. Cooper,et al.  An HRD/DER-independent ER quality control mechanism involves Rsp5p-dependent ubiquitination and ER-Golgi transport , 2002, The Journal of cell biology.

[16]  S. Parvez,et al.  Nitric oxide and neuronal and pancreatic beta cell death. , 2000, Toxicology.

[17]  A. Cerami,et al.  Structure of carbohydrate of hemoglobin AIc. , 1977, The Journal of biological chemistry.

[18]  W. Soeller,et al.  Increased beta-cell apoptosis prevents adaptive increase in beta-cell mass in mouse model of type 2 diabetes: evidence for role of islet amyloid formation rather than direct action of amyloid. , 2003, Diabetes.

[19]  M. Ballmann,et al.  Preferential release of proinsulin relative to insulin in non-insulin-dependent diabetes mellitus. , 1988, Acta endocrinologica.

[20]  E. D. de Koning,et al.  Pancreatic pathology in non-insulin dependent diabetes (NIDDM). , 1995, Diabetes research and clinical practice.

[21]  J. Vanslyke,et al.  Dislocation and degradation from the ER are regulated by cytosolic stress , 2002, The Journal of cell biology.

[22]  S. Kahn,et al.  Islet amyloid: a long-recognized but underappreciated pathological feature of type 2 diabetes. , 1999, Diabetes.

[23]  J. Brown,et al.  Molecular basis for defective secretion of the Z variant of human alpha-1-proteinase inhibitor: secretion of variants having altered potential for salt bridge formation between amino acids 290 and 342 , 1989, Molecular and cellular biology.

[24]  T. Sanke,et al.  Nonsense mutation of islet-1 gene (Q310X) found in a type 2 diabetic patient with a strong family history. , 2000, Diabetes.

[25]  D. Harrison,et al.  The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediate-sized toxic amyloid particles. , 1999, Diabetes.

[26]  Christopher M. Dobson,et al.  Kinetic partitioning of protein folding and aggregation , 2002, Nature Structural Biology.

[27]  Chari Sn,et al.  Glutathione and Its Redox System in Diabetic Polymorphonuclear Leukocytes , 1984 .

[28]  Xiaorong Zhu,et al.  Role of β-Cell Prohormone Convertase (PC)1/3 in Processing of Pro-Islet Amyloid Polypeptide , 2004 .

[29]  R. Riek,et al.  NMR structure of the mouse prion protein domain PrP(121–231) , 1996, Nature.

[30]  C. Betsholtz,et al.  Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[31]  T. Nicotera,et al.  Oxidative damage to DNA in diabetes mellitus , 1996, The Lancet.

[32]  S. Seino,et al.  S20G mutation of the amylin gene is associated with Type II diabetes in Japanese , 2001, Diabetologia.

[33]  T. Hayakawa,et al.  S20G mutation of the amylin gene in Japanese patients with type 2 diabetes. , 2000, Diabetes research and clinical practice.

[34]  M. White,et al.  IRS proteins and the common path to diabetes. , 2002, American journal of physiology. Endocrinology and metabolism.

[35]  M. Gorospe,et al.  P58IPK, a Novel Endoplasmic Reticulum Stress-inducible Protein and Potential Negative Regulator of eIF2α Signaling* , 2003, The Journal of Biological Chemistry.

[36]  A. Kapurniotu,et al.  Amyloidogenicity and cytotoxicity of islet amyloid polypeptide. , 2001, Biopolymers.

[37]  J. Leahy,et al.  Relative Hypersecretion of Proinsulin in Rat Model of NIDDM , 1991, Diabetes.

[38]  R. Sitia,et al.  Formation, isomerisation and reduction of disulphide bonds during protein quality control in the endoplasmic reticulum , 2002, Histochemistry and Cell Biology.

[39]  A. Choi,et al.  The oxidative stress response. , 1995, New horizons.

[40]  T. Sanke,et al.  Missense Mutation of Amylin Gene (S20G) in Japanese NIDDM Patients , 1996, Diabetes.

[41]  D. Ron,et al.  Conformational disease , 2000, Nature Cell Biology.

[42]  M. Alessio,et al.  ERp44, a novel endoplasmic reticulum folding assistant of the thioredoxin family , 2002, The EMBO journal.

[43]  W. Fischer,et al.  Protein Disulfide Bond Formation in the Cytoplasm during Oxidative Stress* , 2004, Journal of Biological Chemistry.

[44]  Anne Bertolotti,et al.  Dynamic interaction of BiP and ER stress transducers in the unfolded-protein response , 2000, Nature Cell Biology.

[45]  G. Cooper,et al.  Amylin gene promoter mutations predispose to Type 2 diabetes in New Zealand Maori , 2003, Diabetologia.

[46]  S. Tyagi,et al.  Islet redox stress: the manifold toxicities of insulin resistance, metabolic syndrome and amylin derived islet amyloid in type 2 diabetes mellitus. , 2002, JOP : Journal of the pancreas.

[47]  R. Gomis,et al.  –To: Poa NR, Cooper GJS, Edgar PF: Amylin gene promoter mutations predispose to Type 2 diabetes in New Zealand Maori. Diabetologia 46: 574–578 , 2003, Diabetologia.

[48]  S. Oyadomari,et al.  Roles of CHOP/GADD153 in endoplasmic reticulum stress , 2004, Cell Death and Differentiation.

[49]  J. Russell,et al.  Nitrosative Injury and Antioxidant Therapy in the Management of Diabetic Neuropathy , 2004, Journal of Investigative Medicine.

[50]  Afshin Samali,et al.  Caspase-12 and ER-stress-mediated apoptosis: the story so far. , 2003, Annals of the New York Academy of Sciences.

[51]  A. Kapurniotu,et al.  Structure-based design and study of non-amyloidogenic, double N-methylated IAPP amyloid core sequences as inhibitors of IAPP amyloid formation and cytotoxicity. , 2002, Journal of molecular biology.

[52]  S. Lenzen,et al.  Relation Between Antioxidant Enzyme Gene Expression and Antioxidative Defense Status of Insulin-Producing Cells , 1997, Diabetes.

[53]  H. Scheraga,et al.  A role for intermolecular disulfide bonds in prion diseases? , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[54]  Josep Vidal,et al.  Increased dietary fat promotes islet amyloid formation and beta-cell secretory dysfunction in a transgenic mouse model of islet amyloid. , 2003, Diabetes.

[55]  X. Chen,et al.  ER stress induces cleavage of membrane-bound ATF6 by the same proteases that process SREBPs. , 2000, Molecular cell.

[56]  P. Westermark,et al.  Amyloid in Human Islets of Langerhans: Immunologic Evidence That Islet Amyloid Polypeptide Is Modified in Amyloidogenesis , 2000, Pancreas.

[57]  G. Merlini,et al.  Pharmaceutical strategies against amyloidosis: old and new drugs in targeting a "protein misfolding disease". , 2004, Current medicinal chemistry.

[58]  E. Araki,et al.  Endoplasmic reticulum stress-mediated apoptosis in pancreatic β-cells , 2002, Apoptosis.

[59]  D. Owens,et al.  INSULIN DEFICIENCY IN NON-INSULIN-DEPENDENT DIABETES , 1989, The Lancet.

[60]  P. Goloubinoff,et al.  Review: mechanisms of disaggregation and refolding of stable protein aggregates by molecular chaperones. , 2001, Journal of structural biology.

[61]  A. Clark,et al.  Islet amyloid and type 2 diabetes: from molecular misfolding to islet pathophysiology. , 2001, Biochimica et biophysica acta.

[62]  J. Bernhagen,et al.  Contribution of advanced glycosylation to the amyloidogenicity of islet amyloid polypeptide. , 1998, European journal of biochemistry.

[63]  Ernest Adeghate,et al.  Molecular and cellular basis of the aetiology and management of diabetic cardiomyopathy: A short review , 2004, Molecular and Cellular Biochemistry.

[64]  J. Morris,et al.  Fibrillar islet amyloid polypeptide (amylin) is internalised by macrophages but resists proteolytic degradation , 1998, Cell and Tissue Research.

[65]  D. Porte,et al.  Disproportionate elevation of immunoreactive proinsulin in Type 2 (non-insulin-dependent) diabetes mellitus and in experimental insulin resistance , 1987, Diabetologia.

[66]  M. Carty,et al.  Diabetes due to a progressive defect in beta-cell mass in rats transgenic for human islet amyloid polypeptide (HIP Rat): a new model for type 2 diabetes. , 2004, Diabetes.

[67]  A. Fink Chaperone-mediated protein folding. , 1999, Physiological reviews.

[68]  D. Yue,et al.  Non-enzymatic glycosylation of tissue protein in diabetes in the rat , 1983, Diabetologia.

[69]  D. Pipeleers,et al.  Glucose sensing in pancreatic beta-cells: a model for the study of other glucose-regulated cells in gut, pancreas, and hypothalamus. , 2001, Diabetes.

[70]  P. Butler,et al.  Replication increases beta-cell vulnerability to human islet amyloid polypeptide-induced apoptosis. , 2003, Diabetes.

[71]  R. Kaufman,et al.  Ligand-independent Dimerization Activates the Stress Response Kinases IRE1 and PERK in the Lumen of the Endoplasmic Reticulum* , 2000, The Journal of Biological Chemistry.

[72]  A. Cerami,et al.  Nonenzymatic glycosylation and the pathogenesis of diabetic complications. , 1984, Annals of internal medicine.

[73]  A. Sinclair,et al.  Modulators of free radical activity in diabetes mellitus: role of ascorbic acid. , 1992, EXS.

[74]  F. Urano,et al.  Transcriptional and translational control in the Mammalian unfolded protein response. , 2002, Annual review of cell and developmental biology.

[75]  T. Sanke,et al.  Enhanced in vitro production of amyloid-like fibrils from mutant (S20G) islet amyloid polypeptide , 2001, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[76]  Masataka Mori,et al.  Endoplasmic reticulum stress and diabetes mellitus. , 2003, Internal medicine.

[77]  E. D. de Koning,et al.  Macrophages and pancreatic islet amyloidosis. , 1998, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.

[78]  M. Hayden,et al.  Islet amyloid, metabolic syndrome, and the natural progressive history of type 2 diabetes mellitus. , 2002, JOP : Journal of the pancreas.

[79]  M. Zou,et al.  Peroxynitrite and vascular endothelial dysfunction in diabetes mellitus. , 2004, Endothelium : journal of endothelial cell research.

[80]  J. Stamler,et al.  S-nitrosylation: spectrum and specificity , 2001, Nature Cell Biology.

[81]  Colin L. Masters,et al.  Neurodegenerative diseases and oxidative stress , 2004, Nature Reviews Drug Discovery.

[82]  L.,et al.  Glucosylation of human collagen in aging and diabetes mellitus. , 1980, The Journal of clinical investigation.

[83]  Ames,et al.  Islet Transplantation in Seven Patients with Type 1 Diabetes Mellitus Using a Glucocorticoid-Free Immunosuppressive Regimen , 2000 .

[84]  Xiaorong Zhu,et al.  Role of beta-cell prohormone convertase (PC)1/3 in processing of pro-islet amyloid polypeptide. , 2004, Diabetes.

[85]  J. Critchley,et al.  The islet amyloid polypeptide (amylin) gene S20G mutation in Chinese subjects: Evidence for associations with type 2 diabetes and cholesterol levels , 2001, Clinical endocrinology.

[86]  S. Tyagi,et al.  "A" is for amylin and amyloid in type 2 diabetes mellitus. , 2001, JOP : Journal of the pancreas.

[87]  Y. Iwamoto,et al.  Serum proinsulin levels at fasting and after oral glucose load in patients with Type 2 (non-insulin-dependent) diabetes mellitus , 1988, Diabetologia.

[88]  H. Scheraga,et al.  Disulfide bonds and protein folding. , 2000, Biochemistry.

[89]  A. Grupe,et al.  Transgenic knockouts reveal a critical requirement for pancreatic β cell glucokinase in maintaining glucose homeostasis , 1995, Cell.

[90]  D. Ron,et al.  Protein translation and folding are coupled by an endoplasmic-reticulum-resident kinase , 1999, Nature.

[91]  P. Butler Apoptosis and the β-Cell in Type 1 and Type 2 Diabetes , 2004, Hormone Research in Paediatrics.

[92]  A. Goldberg,et al.  Protein degradation and protection against misfolded or damaged proteins , 2003, Nature.

[93]  R. Kaufman,et al.  A trip to the ER: coping with stress. , 2004, Trends in cell biology.

[94]  M. R. Nilsson,et al.  Pancreatic beta-cell granule peptides form heteromolecular complexes which inhibit islet amyloid polypeptide fibril formation. , 2004, The Biochemical journal.

[95]  B. Solomon Anti-aggregating antibodies, a new approach towards treatment of conformational diseases. , 2002, Current medicinal chemistry.

[96]  J. Lunec,et al.  Vitamin C metabolites and microangiopathy in diabetes mellitus. , 1987, Diabetes research.

[97]  S. Chari,et al.  Glutathione and Its Redox System in Diabetic Polymorphonuclear Leukocytes , 1984, The American journal of the medical sciences.

[98]  N. Taniguchi,et al.  Increase in the glucosylated form of erythrocyte Cu-Zn-superoxide dismutase in diabetes and close association of the nonenzymatic glucosylation with the enzyme activity. , 1987, Biochimica et biophysica acta.

[99]  C. Verchere,et al.  Islet amyloid polypeptide and type 2 diabetes , 2003, Experimental Gerontology.

[100]  F. Murad,et al.  Diabetes-associated nitration of tyrosine and inactivation of succinyl-CoA:3-oxoacid CoA-transferase. , 2001, American journal of physiology. Heart and circulatory physiology.

[101]  M. Carty,et al.  Islet amyloid-associated diabetes in obese A(vy)/a mice expressing human islet amyloid polypeptide. , 1998, Diabetes.

[102]  D. Steiner,et al.  Effects of beta cell granule components on human islet amyloid polypeptide fibril formation , 1996, FEBS letters.